Ironwood Pharma (IRWD) Misses Q3 EPS by 5c ; Offers Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of $0.02, $0.05 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $91.59 million versus the consensus estimate of $90.9 million.

GUIDANCE:

Ironwood Pharma sees FY2024 revenue of $350-375 million, versus the consensus of $357.1 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• RBC bullish on Kraft Heinz, sees return to growth in 2027
• SEC Issues Guidance to Tokenize Stocks After Clarity Act Failure, Robinhood (HOOD) Gains
• e.l.f. Beauty (ELF) PT Raised to $127 at Bernstein SocGen Group